BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...

and human epidermal growth factor receptor 2 (HER2) genes. These mutations commonly occur in non-small cell lung cancer (NSCLC). More specifically, it aims to treat exon 20 mutations and other ...

BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations) with blockade of EGFR, both mutations that are seen in NSCLC tumours. The oral drug was awarded ...

and the remaining 10% of mutations involve exon 18 and 20. EGFR kinase domain mutations hyperactivate the kinase and confer a dependence on the mutated kinase for the survival of the NSCLC tumour ...

Zipalertinib shows potential in treating exon 20 insertion mutation-positive NSCLC, with a 40% objective response rate in early phase trials. CGEM has a strong financial position with cash ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...

HER2-negative metastatic breast cancer, with promising results, especially when combined with abemaciclib, showing progression-free survival regardless of ESR1 mutation status. Dr Armaghani ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...